ABSTRACT NUMBER: ESOC2026A1477 PERI-PROCEDURAL ANTICOAGULATION MANAGEMENT IN PATIENTS RECEIVING DIRECT ORAL ANTICOAGULANTS OR WARFARIN: A SYSTEMATIC REVIEW AND META-ANALYSIS
Ramsha Khan, Mohammad Bilal Khan, Rory McGovern, Paul Cotter, Priyanka Anauth, Danielle Avanzi · 2026
Read ABSTRACT NUMBER: ESOC2026A1477 PERI-PROCEDURAL ANTICOAGULATION MANAGEMENT IN PATIENTS RECEIVING DIRECT ORAL ANTICOAGULANTS OR WARFARIN: A SYSTEMATIC REVIEW AND META-ANALYSIS by Ramsha Khan, Mohammad Bilal Khan, Rory McGovern, Paul Cotter, Priyanka Anauth, Danielle Avanzi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146991.txt.
Description
Ramsha Khan and co-authors review in 2026 how blood-thinning drugs are handled around surgery and other procedures. Doctors must weigh bleeding risk against clot risk, and newer direct oral drugs have changed the choices once dominated by warfarin. The review gathers recent proof with an eye to practice in the United Kingdom and Ireland.
The team pooled 29 studies covering about 40,000 patients. Pausing the newer drugs led to low rates of major bleeding and very low rates of clots within thirty days. In direct comparisons, keeping the newer drugs going bled less than warfarin care. Adding heparin as a bridge did not cut clot risk, the review finds.
Catalog record
| CREATOR | Ramsha Khan, Mohammad Bilal Khan, Rory McGovern, Paul Cotter, Priyanka Anauth, Danielle Avanzi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |